CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
MolecularMD Corp. has entered into a license agreement to obtain rights to commercialize patent-pending intellectual property pertaining to use of LKB1 for diagnostic, prognostic, and predictive uses in humans in non-small cell lung cancer.
Such patent rights are jointly owned by the Dana-Farber Cancer Institute, Massachusetts General
Hospital, the University of North Carolina at Chapel Hill, and the University of Texas Southwestern Medical Center.
MolecularMD is developing diagnostic assays for LKB1 status, including IHC and next-gen sequencing tests, to support a variety of clinical trials exploring LKB1 clinical utility.
MolecularMD, 503-459-4974